Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Recurrent or refractory advanced renal cell carcinoma (RCC) after two or more previous systemic treatments.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：112
Adult patients with locally advanced or metastatic ROS1 positive non-small cell lung cancer (NSCLC).【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：123
Non small cell lung cancer with MET gene exon 14 mutation positive and unresectable progression and recurrence.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：112
iIndicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease .【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：99
Deucravacitinib is suitable for treating plaque psoriasis.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：145
Momelotinib is indicated for the treatment of intermediate or high-risk myelofibrosis.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：192
Used for relapsed/refractory mantle cell lymphoma and other B-cell malignancies.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：113
Adult patients with moderate to severe rheumatoid arthritis (RA) who have insufficient or intolerant response to various disease modifying antirheumatic drugs (DMARD).【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：126
Daprodustat is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：109
The first-line treatment for metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21L858R substitution mutation.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：174
Used for the treatment of relapsed or refractory FLT3-ITD mutation positive acute myeloid leukemia.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：49
Valcyte treatment for cytomegalovirus infection.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：169
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：[list:visits]2024-09-07
Lucius Pharmaceuticals Relocates from India to Laos: A Five-Year Development Journey of a Generic Dr···【more】
Recommended：[list:visits]2026-24-07
In recent years, Laos has gradually become a major global supply source for generic drugs, leveragin···【more】
Recommended：[list:visits]2026-22-07
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies ···【more】
Recommended：[list:visits]2026-21-07
Company Overview: Industrial Migration from India to LaosLucius Pharmaceuticals (Laos) Co., Ltd. was···【more】
Recommended：[list:visits]2026-20-07
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was···【more】
Recommended：[list:visits]2026-17-07
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosive growth of Laos'···【more】
Recommended：[list:visits]2026-16-07
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
